The replacement of arginine by cysteine at residue 151 in apolipoprotein A-I produces a phenotype similar to that of apolipoprotein A-I(Milano)

Atherosclerosis

Volumn 128, Issue 1, 1997, Pages 121-128

  Bruckert, Eric ^a   Von Eckardstein, Arnold ^b   Funke, Harald ^b   Beucler, Isabel ^a   Wiebusch, Heiko ^b   Turpin, Gérard ^a   Assmann, Gerd ^b  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Apolipoprotein A I; Familial hypoalphalipoproteinemia

Indexed keywords

APOLIPOPROTEIN A1; HIGH DENSITY LIPOPROTEIN;

ADULT; ARTICLE; CASE REPORT; GENE MUTATION; HUMAN; HYPOLIPOPROTEINEMIA; LIPID BLOOD LEVEL; LIPID COMPOSITION; MALE; PHENOTYPE; PRIORITY JOURNAL; SEQUENCE ANALYSIS;

ADULT; AGED; APOLIPOPROTEIN A-I; ARGININE; CHILD; CHOLESTEROL, HDL; CORONARY DISEASE; CYSTEINE; ELECTROPHORESIS; FEMALE; HETEROZYGOTE; HUMANS; LIPOPROTEINS; MALE; MIDDLE AGED; PEDIGREE; PHENOTYPE; PHOSPHATIDYLCHOLINE-STEROL O-ACYLTRANSFERASE; POINT MUTATION; RISK FACTORS; SEQUENCE ANALYSIS, DNA; TANGIER DISEASE;

EID: 0031059508     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(96)05982-5     Document Type: Article

References (41)

1. Gordon D, Rifkind BM. Current concepts: high density lipoproteins: the clinical implications of recent studies. N Engl J Med 1989;321:1311-1315.
2. Hunt SC, Hasstedt SJ, Kuida H, Stults BM, Hopkins PN, Williams, RR. Genetic heritability and common environmental components of resting and stressed blood pressure, lipids and body mass index in Utah pedigrees and twins. Am J Epidemiol 1989;129:625-638.
3. Genest JJ Jr, Bard JM, Fruchart JC, Ordovas JM, Schaefer EJ. Familial hypoalphalipoproteinemia in premature coronary artery disease. Arteriosclerosis Thromb 1993;13:1728-1737.
4. Assmann G, von Eckardstein A, Funke H. High density lipoproteins, reverse transport of cholesterol, and coronary heart disease: insights from mutants. Circulation 1993;87(Suppl. III):III-28-III-34.
5. Breslow JL. Familial disorders of high density lipoprotein metabolism. In: Scriver CR, Beaudet AL, Sly WS, Valle D, (eds). The Metabolic and Molecular Basis of Inherited Disease, 7th edn. New York: McGraw-Hill, 2031-2052.
6. Franceschini G, Sirtori CR, Capurso A, Weisgraber KH, Bersot T, Mahley RW. Decreased HDL cholesterol levels with significant lipoprotein modifications and without clinical atherosclerosis in an Italian family. J Clin Invest 1980;66:892-900.
7. Milano Apoprotein: isolation and characterization of a cysteine containing variant of the A-I apoprotein from human HDL. J Clin Invest 1980;66:901-907.
8. Millano apoprotein identification of the complete kindred and evidence of a dominant genetic transmission. Am J Hum Genet 1985;37:1083-1097.
9. Milano History and clinical profile. In: Sirtori CR, Nichols AV, Franceschini G, (eds). Human apolipoprotein Mutants: Impact on Atherosclerosis and Longevity. New York: Plenum Press, 61-70.
10. 2. Clin Chem 1983;29:2025-2029.
11. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein in plasma without use of a preparative ultracentrifuge. Clin Chem 1972;18:449-456.
12. Sandkamp M, Tambyrajah B, Schriewer H, Assmann G. Simplified turbidimetric determination of apolipoproteins A-I, A-II and B using a microtitre method. J Clin Chem Clin Biochem 1988;26:685-689.
13. Parra HJ, Mezdour H, Ghalim N, Bard N, Fruchart JC. Differential electroimmunoassay of human LpA-I lipoprotein particles on ready-to-use plates. Clin Chem 1990;36:1431-1435.
14. Rader DJ, Castro G, Zech LA, Fruchart JC, Brewer B. In vivo metabolism of apolipoprotein AI on high density lipoprotein particles LpA-I and LpA-LA-II. J Lipid Res 1991;32:1849-1859.
15. Havel RJ, Eder HA, Bragdon JH. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 1955;34:1345-1353.
16. Peterson GL. A simplification of the protein assay method of Lowry et al. which is more generally applicable. Anal Biochem 1977;83:346-356.
17. Menzel HJ, Kladetzky R, Assmann, G. One-step screening method for the polymorphism of apolipoprotein A-I, A-II, and A-IV. J. Lipid Res 1982;23:915-922.
18. Towbin H, Staehlin T, Gordon J. Elektrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA 1975;76:4350-4354.
19. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (London) 1970;227:680-685.
20. von Eckardstein A, Funke H, Henke A, Altland K, Benninghoven A, Assmann G. Apolipoprotein A-I variants: naturally occurring substitutions of proline residues affect plasma concentrations of apolipoprotein A-I. J Clin Invest 1989;84:1722-1730.
21. Nilsson-Ehle P, Ekamn R. Rapid, simple, and specific assays for lipoprotein lipase and hepatic lipase. Artery 1977;3:194-207.
22. Pritchard PH, Mcleod R, Frohlich J, Park MC, Kudchodkar BJ, Lacko AG. Lecithin:cholesterol acyltransferase in familial HDL-deficiency. Biochim Biophys Acta 1988;958:227-234.
23. Gustincich S, Manfioletti G, Del Sal G, Schneider C, Carninci P. A fast method for high-quality genomic DNA extraction from whole human blood. BioTechniques 1991;11:298-302.
24. Funke H, Assman G. Rapid molecular diagnosis of genetic cardiovascular risk factors. Curr Opin Lipidol 1993;4:453-460.
25. Rust S, Funke H, Assman G. Mutagenically separated PCR (MS-PCR): a highly specific one step procedure for easy mutation detection. Nucleic Acids Res 1993;21:3623-3629.
26. Don RH, Cox PT, Wainwright BJ, Baker K, Mattick JS. 'Touchdown' PCR to circumvent spurious priming during gene amplification. Nucleic Acids Res 1991;19:4008.
27. Bruckert E, Emmerich J, Thomas D, Charpak Y, Bichon L, Clergeot A. Influence d'une campagne d'information sur les facteurs de risque cardiovasculaire dans une ville Française (Epernon ville d'étude). Rev Epidémiol Sante Publique, 1994;42:128-137.
28. Karathanasis SK, Zannis VI, Breslow JL. Isolation and characterization of the human apolipoprotein A-I gene. Proc Natl Acad Sci USA 1983;80:6147-6151.
29. Brouilette CG, Anantharamaiah GM. Structural models of human apolipoprotein A-I. Biochim Biophys Acta 1995;1256:103-129.
30. Milano. Disulfide linked dimers increase high density lipoprotein stability and hinder particle interconversion in carrier plasma. J Biol Chem 1990;265:12224-12231.
31. Milano, associated with familial hypoalphalipoproteinemia. J Clin Invest 1993;91:1445-1452.
32. 143_Arg): a mutant that is defective in activating LCAT. Eur J Biochem 1984;144:326-331.
33. Deeb SS, Cheung MC, Peng R et al. A mutation in the human apolipoprotein A-I gene: dominant effect on the level and characteristics of plasma high density lipoproteins. J Biol Chem 1991;266:13651-13660.
34. Funke H, von Eckardstein A, Pritchard PH, Karas M, Albers JJ, Assmann G. A frameshift mutation in the apo A-I gene causes corneal opacities, HDL deficiency and partial LCAT deficiency a syndrom that is distinct from fish eye disease. J Clin Invest 1991;87:375-380.
35. Iowa, associated with hypoalphalipoproteinemia and hereditary systemic amyloidosis. J Lipid Res 1992;33:755-763.
36. Navalesi R, Miccoli R, Odoguardi L et al. Genetically determined absence of HDL-cholesterol and coronary atherosclerosis. Lancet 1995;346:708-709.
37. Milano variant. Biochim. Biophys. Acta 1988;960:73-82.
38. ilano: correlation between high density lipoprotein subclass distribution and hypertriglyceridemia. Arteriosclerosis 1987;7:426-436.
39. Milano. Partial lecithin:cholesterol acyltransferase deficiency due to low levels of a functional enzyme. Biochem Biophys Acta 1990;1043:1-6.
40. Milano apoprotein with plasma lipids and lipoprotein patterns. Atherosclerosis 1985;58:159-174.
41. Milano inhibits carotid thickening induced by perivascular manipulation in rabbits. Circ Res 1995;76:405-410.